ANTIMICROBIAL PROFILE OF SALMONELLA SPECIES ISOLATED AT TERTIARY CARE HOSPITAL WESTERN INDIA
AbstractBackground & Objective: India is home to two infectious diseases caused by Salmonella: typhoid and paratyphoid fever. The medication of choice for S. typhi is ceftriaxone, a third-generation cephalosporin. Study was carried out on the Surveillance of Enteric Fever in India to ascertain the prevalence, clinical manifestation, and trajectory of antimicrobial resistance (AMR). This work aimed to examine the antibiogram profiles of Salmonella typhi found in patient blood cultures. Second, to record how often Salmonella typhi infections occur located in Vadodara, the Antibiotic Susceptibility Test is third. Material and Methods: The Retrospective study was carried out over a period of 12 months after obtaining ethical approval. The freshly drawn venous blood was placed in a blood culture vial. Following identification of pathogen isolates, Kirby-Bauer disc diffusion test was employed to determine antibiotic drug susceptibility as per CLSI rules. Results: Total 10,126 blood samples were collected. In 84 samples (0.83%), 83 instances of Salmonella typhi and 1 instance of Para typhi B. The ratio of males to females was 1:2. Children aged 0–14 years had greater incidence of enteric fever. From July to September, the most instances are solitary. The majority of the Salmonella typhi isolates showed resistance to Ceftriaxone but were sensitive to Ciprofloxacin, Azithromycin and Cotrimoxazole. Conclusion: It has been shown in this review that antibiotic resistance is on the rise among Salmonella species. The use of empirical treatment for enteric fevers should be avoided in favor of third generation cephalosporins, Cefepime, Carbapenem, and azithromycin.
Article Information
27
1403-1408
1190 KB
24
English
IJPSR
Sonia Barve, Sandeep Nanda, Arpita Parmar * and Gopal Koli
Department of Microbiology, Medical College Baroda & SSG Hospital, Vadodara, Gujarat, India.
arpita95parmar@gmail.com
03 December 2024
21 December 2024
28 December 2024
10.13040/IJPSR.0975-8232.16(5).1403-08
01 May 2025